bioAffinity Technologies, Inc. (BIAFW)San Antonio, United States | NasdaqCM
0.10 USD
|
Hot Take ↕ | July 11, 2026, 6:10 a.m. EDT
The security is trapped in a severe structural decline with no path to recovery. Fundamentally, the company is hemorrhaging cash with negative operating and free cash flows, while revenue contracted by nearly 27% year-over-year. The balance sheet is fragile, showing negative returns on both assets and equity, indicating the business is destroying value rather than generating it. Although recent headlines tout a revenue record and a cancer treatment breakthrough, these are insufficient to offset the multi-year price collapse and the stark reality that the market has priced out the business due to deteriorating fundamentals. With no dividend to provide income and a lack of historical price data to suggest a turnaround, the investment case remains overwhelmingly bearish. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 37.761 |
| Revenue per Share | 2.089 |
| Beta | -1.11 |
| Profit Margins | -280.57% |
| Website | https://bioaffinitytech.com |
| Attribute | Value |
|---|---|
| Address1 | 3,300 Nacogdoches Road |
| Address2 | Suite 216 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | -1.11 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 0.815 |
| City | San Antonio |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.1 |
| Current Ratio | 1.363 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.1 |
| Day Low | 0.1 |
| Debt To Equity | 37.761 |
| Display Name | bioAffinity |
| Ebitda | -11,097,579 |
| Ebitda Margins | -1.9607401 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.1 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.1 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.1 - 0.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 4,421,985 |
| Free Cashflow | -6,144,603 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 57 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.33080003 |
| Gross Profits | 1,872,314 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,022-06-28 |
| Language | en-US |
| Long Business Summary | bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas. |
| Long Name | bioAffinity Technologies, Inc. |
| Market | us_market |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_423045573 |
| Net Income To Common | -15,879,947 |
| Open | 0.47 |
| Operating Cashflow | -10,914,307 |
| Operating Margins | -2.67621 |
| Phone | 210 698 5334 |
| Previous Close | 0.1 |
| Price Hint | 4 |
| Price To Book | 0.12269939 |
| Profit Margins | -2.8057 |
| Quick Ratio | 1.188 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.1 |
| Regular Market Day Low | 0.1 |
| Regular Market Day Range | 0.1 - 0.1 |
| Regular Market Open | 0.47 |
| Regular Market Previous Close | 0.1 |
| Regular Market Price | 0.1 |
| Regular Market Time | 1,783,540,543 |
| Regular Market Volume | 0 |
| Return On Assets | -1.07118 |
| Return On Equity | -6.2264695 |
| Revenue Growth | -0.271 |
| Revenue Per Share | 2.089 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | bioAffinity Technologies, Inc. |
| Source Interval | 15 |
| State | TX |
| Symbol | BIAFW |
| Total Cash | 3,098,366 |
| Total Cash Per Share | 0.684 |
| Total Debt | 1,382,591 |
| Total Revenue | 5,659,889 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 0 |
| Website | https://bioaffinitytech.com |
| Zip | 78,217 |